Editor-in-Chief

Ronald W. Ellis
Senior Vice President & Chief Technology Officer
NasVax Ltd; Ness Ziona, Israel

Associate Editors

Sujit K. Bhattacharya

National Institute of Cholera and Enteric Diseases; Kolkata, India

Sally Blower

David Geffen School of Medicine, UCLA; Los Angeles, California USA

Joel Bozue
United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, Maryland USA

Robert S. Daum

University of Chicago; Chicago, Illinois USA

Heather Davis

Coley Pharmaceutical Group; Kanata, Ontario Canada

John Donnelly

Novartis Vaccines and Diagnostics; Siena, Italy

Robert Edelman

University of Maryland School of Medicine; Baltimore, Maryland USA

John Edmunds

Communicable Disease Surveillance Centre; London, UK

Jean-Louis Excler
International AIDS Vaccine Initiative; Trelex, Switzerland

Ian Feavers

National Institute for Biological Standards and Control; Potters Bar, UK

Ricardo Galler

Instituto de Tecnologia em Imunobiologicos, BioManguinhos; Rio de Janeiro, Brasil

Nathalie Garcon

GlaxoSmithKline Biologicals; Rixensart, Belgium

Gregory M. Glenn

Intercell USA Inc.; Gaithersburg, Maryland USA

Michael F. Good

Queensland Institute of Medical Research; Queensland, Australia

Carlos Guzman

Helmholtz Centre for Infection Research; Braunschweig, Germany

Michael G. Hanna, Jr.

Intracel; Frederick, Maryland USA

Leonard C. Harrison

Walter and Eliza Hall Institute of Medical Research; Parkville, Victoria, Australia

Luc Hessel
Sanofi Pasteur MSD; Lyon, France

Genevieve Inchauspe

Transgene; Lyon, France

Mark Kane

Consultant

Helena Kayhty

National Public Health Institute; Helsinki, Finland

Kevin Killeen

Matrivax Corporation; Boston, Massachusetts USA

Keith P. Klugman

Emory University; Atlanta, Georgia USA

Wayne C. Koff

International AIDS Vaccine Institute; New York, New YorkUSA

Reiner Laus

BN ImmunoTherapeutics; Mountain View, California USA

Orin S. Levine

Johns Hopkins School of Public Health; Baltimore, Maryland USA

Philip O. Livington

Memorial Sloan-Kettering Cancer Center; New York, New YorkUSA

Nils Lycke

Univeristy of Göteborg; Göteborg, Sweden

C. Russ Middaugh

University of Kansas; Lawrence, Kansas USA

Timothy F. Murphy

University at Buffalo, SUNY; Buffalo, New York USA

Mark J. Newman

GeoVax, Inc.; Smyrna, Georgia USA

Miguel O'Ryan

University of Chile; Santiago, Chile

Lawrence Paoletti

Harvard Medical School; Boston, Massachusetts USA

Michael Pichichero

University of Rochester Medical Center; Rochester, New York USA

Gerald B. Pier

Harvard Medical School; Boston, Massachusetts USA

Michael W. Russell

University at Buffalo, SUNY; Buffalo, New York USA

Jo Southern
Institute of Child Health; London, UK

Pramod K. Srivastava

Center for Immunotherapy, University of Connecticut; Farmington, Connecticut USA

James Tartaglia

Sanofi Pasteur; Toronto, ON, Canada

Jeffrey Ulmer

Novartis Vaccines; Cambridge, MA USA

Matthias von Herrath

La Jolla Institute for Allergy and Immunology; San Diego, California USA

Brian J. Ward

McGill University; Montreal, QC Canada

Michael Watson

Sanofi-Pasteur; Lyons, France

David B. Weiner

University of Pennsylvania; Philadelphia, Pennsylvania USA

Bruce G. Weniger

Centers for Disease Control and Prevention; Atlanta, Georgia USA

Editorial Board

Sudhir Agrawal

Idera Pharmaceuticals, Inc.; Cambridge, Massachusetts USA

Francis Andre

Atobis S.A.; Brussels, Belgium

Ruth Arnon

Weizmann Institute of Science; Rehovot, Israel

Stephen Black

Kaiser-Permanente; Oakland, California USA

Steven N. Chatfield

Health Protection Agency; London, UK

Robert Chen

Centers for Disease Control and Prevention; Atlanta, Georgia USA

Ron Dagan

Ben-Gurion University; Beer-Sheva, Israel

Angus G. Dalgleish

St. George's Hospital Medical School; London, UK

Anne De Groot

EpiVax, Inc.; Providence Rhode Island USA

R. Gordon Douglas

Consultant; Niantic, Connecticut USA

Kathryn Edwards

Vanderbilt University; Nashville, Tennessee USA

José Esparza

Bill & Melinda Gates Foundation; Seattle, Washington USA

Ian Frazer

University of Queensland; Queensland, Australia

Lance K. Gordon

ImmunoBiologics Corp.

Jaap Goudsmit

Crucell; Amsterdam, The Netherlands

Dan Granoff

Oakland Research Institute; Oakland, California USA

Brian Greenwood

London School of Hygiene and Tropical Medicine; London, UK

Marion F. Gruber

Food and Drug Administration; Rockville, Maryland USA

Ian Gust

University of Melbourne; Parkville, Victoria, Australia

Scott A. Halperin

Dalhousie University; Halifax, NS, Canada

Karl Erik Hellstrom

Harborview Medical Center; Seattle, Washington USA

David Kaslow

Merck Research Laboratories, West Point, Pennsylvania USA

Myron M. Levine

University of Maryland School of Medicine; Baltimore, Maryland USA

Alf Lindberg

Nobel Foundation; Stockholm, Sweden

Philip Minor

National Institute of Biological Standards and Control; Hertfordshire, UK

Thomas Monath

Kleiner Perkins Caufield & Byers; Harvard, Maryland USA

Paul A. Offit

The Children's Hospital of Philadelphia; Philadelphia, Pennsylvania USA

Stanley A. Plotkin

Sanofi Pasteur; Doylestown, Pennsylvania USA

Regina Rabinovich

Bill & Melinda Gates Foundation; Seattle, Washington USA

Philip K. Russell

Albert B. Sabin Vaccine Institute; Potomac, Maryland USA

David Salisbury

UK Department of Health; London, UK

Bing Sun
Chinese Academy of Sciences; Shanghai, China
John Treanor
University of Rochester; Rochester, New York, USA

Howard L. Weiner

Harvard Medical School; Boston, Massachusetts USA

Advertisements